跳至主要内容
临床试验/ACTRN12620000548932
ACTRN12620000548932已完成4 期

Evaluation of an enhanced influenza vaccination schedule in immunocompromised children undergoing treatment for cancer by assessment of cellular and humoral response

CAHS0 个研究点目标入组 78 人开始时间: 2020年5月8日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
78

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
6 Months 至 18 Years(—)
性别
All

入选标准

  • Male or female children of grater than or equal to 6 months and lest than or equal to 18 years of age undergoing therapy for cancer or within 6 months of completion of treatment.
  • Children immunosuppressed as a result of cancer therapy. This includes chemotherapy and radiotherapy but excludes biological agents such as Rituximab.
  • Patients receiving the influenza vaccine outside the hospital will be included provided that the dose and type of vaccine corresponds to the one recommended by the Health Department.

排除标准

  • Known contraindication to influenza vaccine as defined by the Australian Immunisation Handbook 10th Edition.
  • Patients who have received immunoglobulins within the last three months preceding the influenza vaccination.
  • Patients with a history of Guillain-Barre syndrome post influenza vaccine.
  • Patients post autologous or allogeneic haematopoietic stem cell transplantation.
  • Patients with non-malignant haematological disease.

研究者

发起方
CAHS

相似试验